Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Current treatments for relapsed/refractory hematopoietic malignancies such as B-cell
lymphomas (BCLs) and peripheral T-cell lymphomas (PTCLs) are far from satisfactory. CD5 is
widely expressed in multiple subtypes of BCLs and PTCLs but rarely found in normal tissues
except certain types of lymphocytes. Chimeric antigen receptor (CAR) T cells against CD5
offer another potential therapeutic option for patients with relapsed/refractory CD5 positive
hematopoietic malignancies. In the current study, the safety and efficacy of a novel CAR T
cell therapy, termed CT125A cells, are evaluated in patients with relapsed/refractory CD5+
hematopoietic malignancies. The endogenous CD5 in CT125A cells is knocked out via CRISPR/Cas9
genome editing technology to prevent fratricide during CAR T cells manufacturing.